Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children | Infectious Diseases | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
Original Investigation
July 18, 2017

Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children

Author Affiliations
  • 1Department of Pediatrics, St Michael’s Hospital, Pediatric Research, Toronto, Ontario, Canada
  • 2Pediatric Outcomes Research Team, Division of Pediatric Medicine, Department of Pediatrics, the Hospital for Sick Children, Toronto, Ontario, Canada
  • 3Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 4Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
  • 5Child Health Evaluative Sciences, Sick Kids Research Institute, Toronto, Ontario, Canada
  • 6Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
  • 7Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
  • 8The La Ka Shing Knowledge Institute of St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
  • 9Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
  • 10Institute for Clinical Evaluative Sciences, Toronto, Canada
  • 11Faculty of Medicine, University of Toronto, Toronto, Canada
  • 12Department of Public Health Sciences, University of California, Davis, California
  • 13Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada
  • 14Department of Laboratory Medicine & Pathobiology, University of Toronto, Ontario, Canada
JAMA. 2017;318(3):245-254. doi:10.1001/jama.2017.8708
Key Points

Question  Does high-dose vitamin D supplementation (2000 IU/d) help to prevent wintertime viral upper respiratory tract infections compared with standard-dose vitamin D supplementation (400 IU/d) among preschool children?

Findings  In this multisite randomized clinical trial that included 703 children, the number of wintertime laboratory-confirmed viral upper respiratory tract infections was higher in the high-dose group than the standard-dose group, not a statistically significant difference.

Meaning  Vitamin D dosing higher than 400 IU/d may not be indicated for preventing wintertime viral upper respiratory tract infections in children.

Abstract

Importance  Epidemiological studies support a link between low 25-hydroxyvitamin D levels and a higher risk of viral upper respiratory tract infections. However, whether winter supplementation of vitamin D reduces the risk among children is unknown.

Objective  To determine whether high-dose vs standard-dose vitamin D supplementation reduces the incidence of wintertime upper respiratory tract infections in young children.

Design, Setting, and Participants  A randomized clinical trial was conducted during the winter months between September 13, 2011, and June 30, 2015, among children aged 1 through 5 years enrolled in TARGet Kids!, a multisite primary care practice–based research network in Toronto, Ontario, Canada.

Interventions  Three hundred forty-nine participants were randomized to receive 2000 IU/d of vitamin D oral supplementation (high-dose group) vs 354 participants who were randomized to receive 400 IU/d (standard-dose group) for a minimum of 4 months between September and May.

Main Outcome Measures  The primary outcome was the number of laboratory-confirmed viral upper respiratory tract infections based on parent-collected nasal swabs over the winter months. Secondary outcomes included the number of influenza infections, noninfluenza infections, parent-reported upper respiratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyvitamin D levels at study termination.

Results  Among 703 participants who were randomized (mean age, 2.7 years, 57.7% boys), 699 (99.4%) completed the trial. The mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (95% CI, 0.91-1.19) for the high-dose group and 1.03 (95% CI, 0.90-1.16) for the standard-dose group, for a between-group difference of 0.02 (95% CI, −0.17 to 0.21) per child. There was no statistically significant difference in number of laboratory-confirmed infections between groups (incidence rate ratio [RR], 0.97; 95% CI, 0.80-1.16). There was also no significant difference in the median time to the first laboratory-confirmed infection: 3.95 months (95% CI, 3.02-5.95 months) for the high-dose group vs 3.29 months (95% CI, 2.66-4.14 months) for the standard-dose group, or number of parent-reported upper respiratory tract illnesses between groups (625 for high-dose vs 600 for standard-dose groups, incidence RR, 1.01; 95% CI, 0.88-1.16). At study termination, serum 25-hydroxyvitamin D levels were 48.7 ng/mL (95% CI, 46.9-50.5 ng/mL) in the high-dose group and 36.8 ng/mL (95% CI, 35.4-38.2 ng/mL) in the standard-dose group.

Conclusions and Relevance  Among healthy children aged 1 to 5 years, daily administration of 2000 IU compared with 400 IU of vitamin D supplementation did not reduce overall wintertime upper respiratory tract infections. These findings do not support the routine use of high-dose vitamin D supplementation in children for the prevention of viral upper respiratory tract infections.

Trial Registration  clinicaltrials.gov Identifier: NCT01419262

×